Jeffrey Eisele, Chief Development Officer at Apellis Pharmaceuticals, Inc. (APLS), sold 63 shares at $33.09 ($2K) on 2024-12-23, disclosed to the SEC on 2024-12-27.
Seasonal sale ($2k) by Chief Development Officer — this insider has traded APLS in December in at least three consecutive prior years. Pattern-driven, low signal.
Negative factors outweigh the positive ones.
| Filing → |
| APLS | SELL | 2025-01-14 | $8K | — | Filing → |
| APLS | SELL | 2024-01-31 | $145K | — | Filing → |
| APLS | SELL | 2024-01-24 | $940K | — | Filing → |